A5058584326- Acute Lymphoblastic Leukemia research
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- Biochemical and Molecular Research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Cell death mechanisms and regulation
- Protein Degradation and Inhibitors
- T-cell and Retrovirus Studies
- Synthesis and Characterization of Heterocyclic Compounds
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Nuclear Structure and Function
- Cancer therapeutics and mechanisms
- Cancer-related gene regulation
- Protein Kinase Regulation and GTPase Signaling
- Synthesis and biological activity
- Hemoglobinopathies and Related Disorders
- Ubiquitin and proteasome pathways
- Autophagy in Disease and Therapy
- Wnt/β-catenin signaling in development and cancer
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Mesenchymal stem cell research
- Research on Leishmaniasis Studies
- Polyamine Metabolism and Applications
University of Modena and Reggio Emilia
2023-2025
Istituto di Genetica Molecolare
2018-2022
Istituto Ortopedico Rizzoli
2007-2022
National Research Council
2012-2021
Istituto di Scienze Marine del Consiglio Nazionale delle Ricerche
2020-2021
Bologna Research Area
2013-2020
Institute of Molecular Genetics
2014
University of Bologna
2007-2013
Weatherford College
2013
Consorzio Roma Ricerche
2013
Recent findings have highlighted that constitutively active phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling is a common feature T-cell acute lymphoblastic leukemia (T-ALL), where it upregulates cell proliferation, survival, and drug resistance. These observations lend compelling weight to the application PI3K/Akt/mTOR inhibitors in therapy T-ALL. Here, we analyzed therapeutic potential novel dual PI3K/mTOR inhibitor NVP-BEZ235, an orally bioavailable...
Recent investigations have documented that constitutively activated phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling is a common feature T-cell acute lymphoblastic leukemia (T-ALL), where it strongly influences growth and survival. These findings lend compelling weight for the application PI3K/Akt/mTOR inhibitors in T-ALL. However, our knowledge T-ALL limited not clear whether could be an effective innovative therapeutic strategies. Here, we analyzed...
Lipid signaling pathways are involved in cell growth, differentiation, and apoptosis, could have a role the progression of myelodysplastic syndromes (MDS) into acute myeloid leukemia (AML). Indeed, recent studies showed that phosphoinositide-phospholipase (PI-PL)Cbeta1 mono-allelic deletion correlates with higher risk AML evolution. Also, single patient treated azacitidine, DNA methyltransferase inhibitor currently used MDS, displayed direct correlation between PI-PLCbeta1 gene expression...
Abstract To potentiate the response of acute myelogenous leukemia (AML) cells to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) cytotoxicity, we have examined efficacy a combination with perifosine, novel phosphatidylinositol-3-kinase (PI3K)/Akt signaling inhibitor. The rationale for using such is that perifosine was recently described increase TRAIL-R2 receptor expression and decrease cellular FLICE-inhibitory protein (cFLIP) in human lung cancer cell lines. Perifosine...